Copyright 2001 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2001
Ondansetron is a selective serotonin receptor (5-HT3) antagonist that is widely used as an antiemetic agent for highly, and now increasingly for moderately, emetogenic chemotherapy.1,2 Although this drug is very well tolerated, the US Food and Drug Administration has received 24 reports of adverse reactions associated with various clinical manifestations of anaphylaxis.3 Another report described 2 cases of anaphylactoid reactions associated with previous ondansetron exposure.4 We report a case of anaphylaxis in a patient with no prior ondansetron exposure.
Weiss KS. Anaphylactic Reaction to Ondansetron. Arch Intern Med. 2001;161(18):2263. doi:
Customize your JAMA Network experience by selecting one or more topics from the list below.